|

Samtasu Post-marketing General Drug Use-results Survey in Patients with Volume Overload in Heart Failure.

RECRUITINGSponsored by Otsuka Pharmaceutical Co., Ltd.
Actively Recruiting
SponsorOtsuka Pharmaceutical Co., Ltd.
Started2023-03-03
Est. completion2025-11-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05712746

Summary

To confirm the safety of tolvaptan sodium phosphate in patients with volume overload in heart failure.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

\-

Exclusion Criteria:

* patients with a known hypersensitivity to Tolvaptan sodium phosphate or Tolvaptan

Conditions2

Heart DiseaseHeart Failure

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.